ARVINAS, INC. (ARVN) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $100.00K; Additional Paid in CapitalUSD $2.16B; Treasury Stock, Common, ValueUSD $91.90M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $100.00K; Additional Paid in CapitalUSD $2.15B; Treasury Stock, Common, ValueUSD $91.90M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $100.00K; Additional Paid in CapitalUSD $2.14B; Treasury Stock, Common, ValueUSD $91.90M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $100.00K; Additional Paid in CapitalUSD $2.13B; Treasury Stock, Common, ValueUSD (m).
ARVINAS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Treasury Stock, Common, Value USD | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | Treasury Stock, Value, Acquired, Cost Method USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Shares, Acquired shares | Treasury Stock Acquired, Average Cost Per Share USD/shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $100.00K | $2.16B | $91.90M | (m) | $-800.00K | $-1.50B | $562.20M | 10.00M | (m) | (m) | 3 month · $5.90M 6 month · $18.00M | (m) | (m) |
| 2026-03-31 | $0.00 | $100.00K | $2.15B | $91.90M | (m) | $-400.00K | $-1.67B | $386.80M | 10.00M | (m) | (m) | 3 month · $12.10M | (m) | (m) |
| 2025-12-31 | $0.00 | $100.00K | $2.14B | $91.90M | (m) | $1.20M | $-1.61B | $433.90M | 10.00M | 12 month · $91.90M | (m) | 12 month · $44.00M | 12 month · 10.01M | 12 month · 9.09 |
| 2025-09-30 | $0.00 | $100.00K | $2.13B | (m) | $20.30M | $1.40M | $-1.54B | $564.40M | 2.60M | 3 month · $20.30M 9 month · $20.30M | (m) | 3 month · $10.10M 9 month · $35.50M | 3 month · 2.56M 9 month · 2.56M | 3 month · 7.91 9 month · 7.91 |
| 2025-06-30 | $0.00 | $100.00K | $2.12B | (m) | (m) | $1.00M | $-1.51B | $609.30M | (m) | (m) | (m) | 3 month · $10.40M 6 month · $25.40M | (m) | (m) |
| 2025-03-31 | $0.00 | $100.00K | $2.11B | (m) | (m) | $1.50M | $-1.45B | $660.10M | (m) | (m) | (m) | 3 month · $15.00M | (m) | (m) |
| 2024-12-31 | $0.00 | $100.00K | $2.09B | $0.00 | $0.00 | $1.00M | $-1.53B | $561.70M | 0.00 | (m) | (m) | 12 month · $88.20M | (m) | (m) |
| 2024-09-30 | $0.00 | $100.00K | $2.07B | (m) | (m) | $4.10M | $-1.49B | $586.00M | (m) | (m) | (m) | 3 month · $24.70M 9 month · $64.90M | (m) | (m) |
| 2024-06-30 | $0.00 | $100.00K | $2.04B | (m) | (m) | $-3.80M | $-1.44B | $600.20M | (m) | (m) | (m) | 3 month · $21.60M 6 month · $40.20M | (m) | (m) |
| 2024-03-31 | $0.00 | $100.00K | $2.02B | (m) | (m) | $-4.40M | $-1.40B | $609.70M | (m) | (m) | (m) | 3 month · $18.60M | (m) | (m) |
| 2023-12-31 | $0.00 | $100.00K | $2.00B | (m) | (m) | $-3.10M | $-1.33B | $660.00M | (m) | (m) | 12 month · $17.00M | 12 month · $71.60M | (m) | (m) |
| 2023-09-30 | (m) | $100.00K | $1.64B | (m) | (m) | $-9.20M | $-1.18B | $457.20M | (m) | (m) | 3 month · $1.10M 9 month · $1.10M | 3 month · $16.70M 9 month · $54.90M | (m) | (m) |
| 2023-06-30 | (m) | $100.00K | $1.59B | (m) | (m) | $-12.20M | $-1.11B | $463.60M | (m) | (m) | (m) | 3 month · $18.30M 6 month · $38.20M | (m) | (m) |
| 2023-03-31 | (m) | $100.00K | $1.57B | (m) | (m) | $-12.60M | $-1.05B | $511.00M | (m) | (m) | (m) | 3 month · $19.90M | (m) | (m) |
| 2022-12-31 | $0.00 | $100.00K | $1.55B | (m) | (m) | $-19.20M | $-965.40M | $564.90M | (m) | (m) | (m) | 12 month · $75.50M | (m) | (m) |
| 2022-09-30 | (m) | $100.00K | $1.53B | (m) | (m) | $-24.80M | $-882.50M | $621.50M | (m) | (m) | (m) | 3 month · $18.80M 9 month · $55.40M | (m) | (m) |
| 2022-06-30 | (m) | $100.00K | $1.51B | (m) | (m) | $-22.00M | $-816.30M | $670.60M | (m) | (m) | (m) | 3 month · $20.00M 6 month · $36.60M | (m) | (m) |
| 2022-03-31 | (m) | $0.00 | $1.49B | (m) | (m) | $-18.70M | $-746.30M | $723.30M | (m) | (m) | (m) | 3 month · $16.60M | (m) | (m) |
| 2021-12-31 | (m) | $0.00 | $1.47B | (m) | (m) | $-4.60M | $-682.90M | $781.70M | (m) | (m) | 12 month · $4.60M | 12 month · $57.10M | (m) | (m) |
| 2021-09-30 | (m) | $52.77K | $1.45B | (m) | (m) | $-676.65K | $-629.89M | $817.70M | (m) | (m) | 3 month · $4.60M 9 month · $4.60M | 3 month · $15.20M 9 month · $40.10M | (m) | (m) |
| 2021-06-30 | (m) | $48.99K | $1.17B | (m) | (m) | $-486.54K | $-583.14M | $582.90M | (m) | (m) | (m) | 3 month · $14.60M 6 month · $24.90M | (m) | (m) |
| 2021-03-31 | (m) | $48.79K | $1.15B | (m) | (m) | $-242.75K | $-532.85M | $615.20M | (m) | (m) | (m) | 3 month · $10.30M | (m) | (m) |
| 2020-12-31 | (m) | $0.00 | $1.13B | (m) | (m) | $600.00K | $-491.90M | $642.20M | (m) | (m) | 12 month · $28.10M | 12 month · $30.20M | (m) | (m) |
| 2020-09-30 | (m) | $40.10K | $654.34M | (m) | (m) | $1.08M | $-450.34M | $205.12M | (m) | (m) | (m) | 3 month · $8.25M 9 month · $22.12M | (m) | (m) |
| 2020-06-30 | (m) | $38.83K | $615.60M | (m) | (m) | $1.66M | $-419.52M | $197.78M | (m) | (m) | (m) | 3 month · $7.75M 6 month · $13.87M | (m) | (m) |
| 2020-03-31 | (m) | $38.67K | $606.57M | (m) | (m) | $-602.61K | $-394.30M | $211.71M | (m) | (m) | (m) | 3 month · $6.12M | (m) | (m) |
| 2019-12-31 | (m) | $38.46K | $599.10M | (m) | (m) | $107.58K | $-372.56M | $226.60M | (m) | (m) | (m) | 12 month · $20.10M | (m) | (m) |
| 2019-09-30 | (m) | $33.08K | $485.44M | (m) | (m) | $196.65K | $-351.51M | $134.16M | (m) | (m) | (m) | 3 month · $4.60M 9 month · $15.09M | (m) | (m) |
| 2019-06-30 | (m) | $31.52K | $450.01M | (m) | (m) | $300.15K | $-333.83M | $116.51M | (m) | (m) | (m) | 3 month · $5.31M 6 month · $10.49M | (m) | (m) |
| 2019-03-31 | (m) | $31.37K | $444.30M | (m) | (m) | $80.03K | $-316.67M | $127.74M | (m) | (m) | (m) | 3 month · $5.18M | (m) | (m) |
| 2018-12-31 | (m) | $31.24K | $439.12M | (m) | (m) | $-217.72K | $-302.26M | $136.60M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $3.68K | $7.38M | (m) | (m) | $-47.22K | $-286.18M | $-278.84M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-158.52M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-136.78M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $-9.75K | $-62.42M | $-61.23M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-52.02M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-32.88M | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |